|
|
Volumn 2, Issue 1, 2004, Pages 17-23
|
|
Rational use of oral bisphosphonates for the treatment of osteoporosis.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BISPHOSPHONIC ACID DERIVATIVE;
AGED;
CANADA;
CLINICAL TRIAL;
COMPARATIVE STUDY;
CONTROLLED CLINICAL TRIAL;
DOSE RESPONSE;
DRUG ADMINISTRATION;
FEMALE;
HOSPITALIZATION;
HUMAN;
MALE;
MAXIMUM TOLERATED DOSE;
MIDDLE AGED;
ORAL DRUG ADMINISTRATION;
OSTEOLYSIS;
OSTEOPOROSIS;
PATHOLOGIC FRACTURE;
POSTMENOPAUSE OSTEOPOROSIS;
PROGNOSIS;
RANDOMIZED CONTROLLED TRIAL;
REVIEW;
RISK ASSESSMENT;
TREATMENT OUTCOME;
ADMINISTRATION, ORAL;
AGED;
BONE RESORPTION;
CANADA;
DIPHOSPHONATES;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG ADMINISTRATION SCHEDULE;
FEMALE;
FRACTURES, SPONTANEOUS;
HUMANS;
MALE;
MAXIMUM TOLERATED DOSE;
MIDDLE AGED;
OSTEOPOROSIS;
OSTEOPOROSIS, POSTMENOPAUSAL;
PROGNOSIS;
RANDOMIZED CONTROLLED TRIALS;
RISK ASSESSMENT;
SEVERITY OF ILLNESS INDEX;
TREATMENT OUTCOME;
|
|
EID: 23944438479
PISSN: 15441873
EISSN: None
Source Type: Journal
DOI: 10.1007/s11914-004-0010-6 Document Type: Review |
|
Times cited : (15)
|
|
References (46)
|
